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Platinum-based chemotherapeutic regimens are ultimately unsuccessful due to intrinsic or acquired drug resistance. Understanding
the molecular basis for platinum drug sensitivity/resistance is necessary for the development of new drugs and therapeutic regimens.
In an effort to identify such determinants, we evaluated the expression of approximately 4000 genes using cDNA microarray
screening in a panel of 14 unrelated human ovarian cancer cell lines derived from patients who were either untreated or treated with
platinum-based chemotherapy. These data were analysed relative to the sensitivities of the cells to four platinum drugs (cis-
diamminedichloroplatinum (cisplatin), carboplatin, DACH-(oxalato)platinum (II) (oxaliplatin) and cis-diamminedichloro (2-
methylpyridine) platinum (II) (AMD473)) as well as the proliferation rate of the cells. Correlation analysis of the microarray data
with respect to drug sensitivity and resistance revealed a significant association of Stat1 expression with decreased sensitivity to
cisplatin (r¼0.65) and AMD473 (r¼0.76). These results were confirmed by quantitative RT–PCR and Western blot analyses. To
study the functional significance of these findings, the full-length Stat1 cDNA was transfected into drug-sensitive A2780 human
ovarian cancer cells. The resulting clones that exhibited increased Stat1 expression were three- to five-fold resistant to cisplatin and
AMD473 as compared to the parental cells. The effect of inhibiting Jak/Stat signalling on platinum drug sensitivity was investigated
using the Janus kinase inhibitor, AG490. Pretreatment of platinum-resistant cells with AG490 resulted in significant increased
sensitivity to AMD473, but not to cisplatin or oxaliplatin. Overall, the results indicate that cDNA microarray analysis may be used
successfully to identify determinants of drug sensitivity/resistance and future functional studies of other candidate genes from this
database may lead to an increased understanding of the drug resistance phenotype.
British Journal of Cancer (2005) 92, 1149–1158. doi:10.1038/sj.bjc.6602447 www.bjcancer.com
Published online 22 February 2005
& 2005 Cancer Research UK
Keywords: cisplatin; drug resistance; ovarian cancer; microarray; Stat1
                                                       
Since its introduction into the clinic 30 years ago, cis-diamminedi-
chloroplatinum (II) (cisplatin) has had a significant impact on the
treatment of solid tumours. Alone or in combination with other
chemotherapeutic drugs, cisplatin and its less toxic analogue,
carboplatin, are curative for testicular cancer and also prolong
survival in other tumours including those of the ovary, lung,
bladder and head and neck (Johnson et al, 2001). Successful
treatment of tumours with these drugs, however, is limited by the
development of tumour cell resistance. This has fuelled a search
for new platinum analogues that exhibit nonoverlapping cytotoxi-
city profiles in cisplatin/carboplatin-refractory tumours. The
development of such analogues has been achieved primarily
through modification or substitution of the diammine carrier
ligands of the parent compound.
The DACH platinum compounds are a series of complexes
containing a diaminocyclohexane carrier ligand (Connors et al,
1972; Kidani et al,1 9 7 6 ;R i x eet al, 1996). These compounds have a
unique cytotoxicity profile as compared to cisplatin and exhibit
collateral sensitivity in some cisplatin-resistant cell lines (Burchenal
et al, 1980). The clinical development of DACH platinum drugs
was initially hampered due to unacceptable toxicities; however,
significant interest has been rekindled by the development
of the less toxic analogue, oxaliplatin ((DACH-(oxalato)platinum
(II)). Oxaliplatin has shown activity alone or in combination with
5-fluorouracil/leucovorin in colon cancer, a disease that
was previously considered to be unresponsive to platinum drugs
(Cvitkovic and Bekradda, 1999). In addition to oxaliplatin,
another unique platinum analogue, cis-diamminedichloro(2-methyl-
pyridine) platinum (II) (AMD473), has been developed in an
effort to circumvent cisplatin resistance. AMD473 is a ‘sterically
hindered’ platinum complex that was designed to react preferen-
tially with nucleic acids over thiol-containing molecules
such as glutathione (Kelland, 1999). Studies have shown that
AMD473 exhibits activity against acquired cisplatin-resistant cell
lines and is active when administered by oral or intraperitoneal
routes in human ovarian cancer xenografts (Raynaud et al, 1997;
Holford et al 1998).
Received 23 July 2004; revised 12 November 2004; accepted 11 January
2005; published online 22 February 2005
*Correspondence: Dr SW Johnson, Department of Pharmacology, BRB
II/III – Rm. 1020, 421 Curie Blvd., University of Pennsylvania, Philadelphia,
PA 19104-6160, USA; E-mail: johnson@pharm.med.upenn.edu
Supplementary Data for this manuscript is available at www.johnsonlab.
org
British Journal of Cancer (2005) 92, 1149–1158
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sTumour cells may exhibit intrinsic platinum resistance or may
acquire resistance following multiple cycles of platinum-based
chemotherapy. Platinum resistance is considered multifactorial
and includes mechanisms that limit the formation of platinum–
DNA adducts and mechanisms that prevent cell death following
drug-induced damage (Johnson et al, 1998). More specifically,
these mechanisms include decreased drug uptake, increased drug
inactivation, increased repair of platinum–DNA adducts and
increased platinum–DNA damage tolerance. Some of these
mechanisms may be specific to the type of platinum drug used,
whereas others may be pleiotropic. As the molecular basis for
platinum resistance remains largely undefined, the identification
of the specific genes/pathways involved will hopefully lead to new
strategies to treat platinum-refractory tumours or prevent
resistance from emerging.
The development of drug resistance models has been instru-
mental to the identification of resistance mechanisms. These
models have been established primarily by repeatedly exposing
drug-sensitive cells to chemotherapeutic drugs in vitro. Although
many putative drug resistance mechanisms have been identified
and characterised in these types of models, their relevance to
clinical drug resistance has been difficult to prove. Therefore, it is
important to study resistance models derived from tumours in
order to identify clinically relevant resistance mechanisms. One
such model that we have extensively studied is a panel of unrelated
human ovarian cancer cell lines derived from patients who were
either untreated or treated with platinum-based chemotherapy.
The cell lines of this panel exhibit a wide range of sensitivity to
cisplatin (40-fold) and other chemotherapeutic drugs (Johnson
et al, 1997). In the present study, we have used this panel of cell
lines to identify candidate genes associated with sensitivity/
resistance to four platinum drugs by cDNA microarray screening.
Although semiquantitative, this technique can delineate patterns of
gene expression and identify clusters of up or downregulated genes
within a group of samples. Our results indicate that coupled with
the appropriate validation steps, this method is useful for the
identification of genes involved in chemoresistance.
MATERIALS AND METHODS
Cell culture
The human ovarian cancer cell lines used in this study were
isolated from patients who were either untreated or treated with
platinum-based chemotherapy (Table 1). The OAW42 cell line,
originally described by Hill et al (1984), was obtained from the
European Collection of Cell Cultures. Cells were maintained at
371C in a humidified incubator containing 5% CO2 in RPMI 1640
medium (Life Technologies, Grand Island, NY, USA) supplemen-
ted with 10% (vv
 1) foetal calf serum (Atlanta Biologicals, Atlanta,
GA, USA), 100mgml
 1 streptomycin, 100Uml
 1 penicillin,
0.3mgml
 1 glutamine and 0.25Uml
 1 insulin (porcine).
Cytotoxicity assay
Cytotoxicity (IC50) values for the four platinum drugs were
determined using the 3-(4,5-dimethyl-thizol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) assay (Hansen et al, 1989). Cells (100–
4000well
 1) were plated in 150ml of medium/well in 96-well
microtitre plates. Following overnight incubation, cells were
exposed to a range of drug concentrations. After 72h, 40mlo f
5mgml
 1 MTT were added per well and the plates were incubated
for 2h at 371C. The cells were then lysed by adding 100ml of 20%
(wv
 1) sodium dodecyl sulphate (SDS), 50% (vv
 1) N,N-
dimethylformamide (pH 4.7), and then incubating overnight at
room temperature. The absorbance at 595nm was determined
using a Bio-Tek ELX800 microplate reader (Bio-Tek Instruments,
Winooski, VT, USA). The reported values are the average of
triplicate determinations made on at least two separate occasions.
Relationships between the drugs were assessed by the Spearman’s
rank correlation test using p0.05 as a significance threshold. For
studies using tyrphostin B42 (AG490 – Calbiochem), cells were
pretreated for 1h with the inhibitor followed by the addition of
platinum drugs as described above.
Cell doubling time
Doubling time was determined using a similar assay as described
by Ross et al (2000). Cells (150ml) were plated at two densities into
six wells of a 96-well microtitre plate. At 24, 48 and 72h time
points, 40ml of 5mgml
 1 MTT were added per well. After 2h at
371C, the cells were lysed by adding 100ml of 20% (wv
 1) SDS,
50% (vv
 1) N,N-dimethylformamide (pH 4.7), and then incubated
overnight at room temperature. The absorbance of each well at
595nm was recorded. Doubling times were calculated using the
formula: N/N0¼e
kt, where N is the corresponding value at time
zero. The constant k was calculated for each cell line between 24
and 72h, the period of time in which the cell proliferation rate was
maximal. The doubling time was then determined using the above
formula with N/N0¼2.
RNA isolation
Total cellular RNA was extracted from the cell lines by a
modification of the single-step method described by Chomczynski
and Sacchi (Chomczynski and Sacchi, 1987; Chomczynski and
Mackey, 1995) using guanidine isothiocyanate. RNA was pre-
cipitated from the aqueous phase by the addition of isopropanol.
Following centrifugation, RNA pellets were washed with 75%
ethanol, resuspended in DEPC-treated water and treated with
DNase I. RNA integrity was assessed by ethidium bromide staining
following agarose-gel electrophoresis and quantitated by absor-
bance at 260nm. Samples were stored at  801C under ethanol.
Preparation of cDNA probes
Total RNA (2.0mg) was combined in a 1.5ml microcentrifuge tube
with 10mg of oligo-dT (Research Genetics) in a final volume of
10ml and incubated at 701C for 10min and placed on ice for 5min.
The cDNA synthesis reaction contained a mixture of 6.0mlo f
5 first strand Buffer (Life Technologies), 1.0ml 100mM DTT,
1.5ml dA/dG/dT (10mM each), 10ml[ a
 33P]dCTP (100mCi), and
1.5ml MMLV reverse transcriptase (200Uml
 1). Samples were
incubated at 371C for 1.5h. Nucleotides and unincorporated
33P
were removed by gel chromatography using Micro Bio-Spin 30
Table 1 Human ovarian cancer cell lines used in this study
Cell line Phenotype
A2780 Untreated ovarian tumour
A1847 Untreated ovarian tumour
SKOV3 Ovarian tumour, cisplatin sensitive
PEO1 Ovarian tumour, cisplatin sensitive
PEO4 Ovarian tumour (PEO1) after patient became refractory
OVCAR2 Ovarian tumour from a cisplatin-refractory patient
OVCAR3 Ovarian tumour from a cisplatin-refractory patient
OVCAR4 Ovarian tumour from a cisplatin-refractory patient
OVCAR5 Untreated ovarian tumour
OVCAR7 Untreated ovarian tumour
OVCAR8 Ovarian tumour from a platinum-refractory patient
OVCAR10 Ovarian tumour from a platinum-refractory patient
UPN251 Ovarian tumour from a platinum/paclitaxel-refractory patient
OAW42 Ovarian tumour, cisplatin sensitive
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were denatured by incubating at 1001C for 3min and placed on ice.
cDNA microarray screening
Microarray analysis was carried out using the recommended
procedure supplied by Research Genetics Inc. The Named Human
Genes filters (GF211), which are spotted with 4132 cDNA elements,
were prehybridized in 5ml MicroHyb solution (Research Genetics)
containing 5mg of poly-dA overnight at 421C in a hybridisation
oven (Model H010-1, Stovall Life Science Inc., Greensboro, NC,
USA). The denatured probes were then added to this solution and
incubated 14–18h at 421C. The membranes were washed briefly
with 200ml of wash buffer I (2 SSC, 1% SDS) at room
temperature, followed by two 20min washes with the same buffer
at 501C, and two washes with 200ml of wash buffer II (0.5 SSC,
1% SDS) at 551C for 20min. The filters were removed, immediately
wrapped in plastic and imaged on a Storm 840 phosphorimager
(Molecular Dynamics, Sunnyvale, CA, USA), following a 5-day
exposure to the imaging plate. For reuse, membranes were stripped
by incubating for 20min in 0.5% (wv
 1) SDS that had been
brought to 1001C and repeating. Stripped filters were reimaged
following a 24h exposure to insure complete removal of radio-
activity.
Data analysis
The data obtained from the phosphorimager was analysed using
Pathways software (Research Genetics). This software utilises the
raw image obtained from the phosphorimager in order to align the
image and determine expression values for all of the elements. The
raw data were downloaded into Microsoft Excel for final analysis.
Also, a signal-to-noise ratio was obtained for all of the hybridised
filters by dividing the mean of the raw data by the background
value. Only the hybridisations that yielded signal-to-noise ratios
above 1.5 were used in the subsequent data analysis. In order to
correct for background, the average value of the lowest 1% of the
genes expressed for each sample was subtracted from each raw
data point to obtain a background corrected expression value. The
data were then normalised by subtracting the mean and dividing
by the standard deviation of the expression values for the entire
data set for each cell line (global means method). RNA from each
cell line was subject to microarray analysis at least twice. The
normalised data obtained from duplicated hybridisations were
averaged to obtain a final data set. Reproducibility of the data was
assessed by calculating a percent error (s.d./mean 100) for each
gene element.
The data were cropped to a final set of 2000 elements by
eliminating genes with relatively low expression and low standard
deviation across the panel of cell lines. This was carried out by
measuring the expression of 51 genes in each of the 14 cell lines by
quantitative ‘real-time’ PCR. We considered a gene ‘validatable’ if
the Spearman and/or Pearson correlation coefficient was X0.6 for
the microarray/PCR data. A factor (P) was calculated by multi-
plying the average of the expression of each gene for all the cell
lines with the standard deviation. Genes with P-values below
100000 could not be consistently validated by RT–PCR and were
eliminated. We also eliminated genes in which the median
expression value across the cell lines was low (see Web Supplement
for more detail).
The identification of candidate drug sensitivity/resistance genes
was carried out by several statistical methods. Correlation
coefficients (Pearson and Spearman) were calculated for the
expression of each gene relative to the proliferation rate and
platinum drug sensitivity for the entire panel of cell lines. The
correlation coefficients were then ranked from highest to lowest
and vice versa in order to obtain a list of genes associated with
proliferation and/or platinum drug sensitivity. Hierarchical
clustering was carried out using the Cluster and TreeView
programs developed by Eisen et al (1998). Data for each gene
element were normalised and mean centred using the software.
Quantitative RT–PCR
Validation of the expression of candidate genes identified by
microarray analysis was carried out by ‘real-time’ quantitative PCR
using a Roche LightCycler with SYBR green chemistry. Total RNA
(2mg) from each sample was reverse transcribed using the
Superscript II First Strand cDNA synthesis kit (Invitrogen Inc.,
Huntsville, AL, USA). Reaction conditions were optimised for each
primer set. Measurements were made from each cDNA reaction in
duplicate and normalised based on the average of the normalised
expression of four housekeeping genes. The housekeeping genes
were chosen using the microarray data and selection was limited to
the genes that exhibited the low variability in expression across the
panel of ovarian cancer cell lines. Primer sequences and reaction
conditions are listed at www.realtimeprimers.org.
Western blot analysis
Cell extracts were prepared by lysing cells grown in 10cm culture
dishes with 50mM Tris-HCl, pH 7.4, containing 1% NP-40, 0.25%
sodium deoxycholate, 150mM NaCl, 1mM EDTA, 1mM PMSF,
1mgml
 1 protease inhibitors, 1mM NaF and 1mM Na3VO4. Protein
concentrations were determined using the Bradford protein assay
and equal amounts of extract (15mg) were resolved on 10% SDS–
polyacrylamide gels. Following transfer to nylon membranes, the
blots were blocked overnight at 41C in Tris-buffered saline (TBS)
containing 0.1% Tween-20 detergent and 5% nonfat dry milk.
Membranes were then incubated for 1h at room temperature with
a 1:2000 dilution of monoclonal mouse anti-Stat1 antibody (Santa
Cruz, Santa Cruz, CA, USA). Following three washes in TBS-T, the
membranes were incubated in 1:3000 dilution of horseradish
peroxidase-linked anti-mouse secondary antibody (Santa Cruz,
Santa Cruz, CA, USA). Following several washes in TBS-T, the
Stat1 protein bands were visualised by chemiluminescence (ECL,
Amersham Biosciences, Piscataway, NJ, USA). Individual protein
bands were quantitated by densitometry.
Transfections
The full-length Stat1-pcDNA3.1 GeneStorm expression ready
plasmid was purchased from Invitrogen Inc. (Huntsville, AL,
USA). The plasmid was transfected into A2780 cells using
Lipofectamine and selected with zeocin. Individual clones were
isolated, propagated and examined for Stat1 expression by
Western blotting and for drug sensitivity using the MTT assay.
RESULTS
The human ovarian cancer cell lines used in this study are listed in
Table 1. These cell lines were established from patients who were
either untreated or treated with platinum-based chemotherapy.
Seven of these cell lines represent patients who failed chemother-
apy. The others are derived from chemotherapy-naı ¨ve patients;
however, several of these (A1847, SKOV3, OVCAR5, OVCAR7)
exhibit intrinsic platinum resistance. The only two related cell lines
are PEO1 and PEO4. The latter was established from the same
patient as PEO1; however, this was carried out after the patient
developed resistance to platinum-based chemotherapy. Cell
doubling times and platinum drug sensitivities were measured in
this cell line panel using an MTT assay (Table 2). The range in
proliferation rate was approximately three-fold with A2780 having
the shortest doubling time (13.5h) and OVCAR7 the longest
(44.7h). A wide range of sensitivity to the four platinum drugs was
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observed between the cytotoxicity profiles of cisplatin and
carboplatin (r¼0.95), whereas oxaliplatin did not show a high
correlation with the sensitivity pattern of these two drugs (r¼0.37
and 0.35, respectively). Although not as significant, there was an
association between cisplatin and carboplatin sensitivities with
that of AMD473 (r¼0.62 and 0.60, respectively). Significant
similarities were also observed between oxaliplatin and AMD473
(r¼0.74). Decreased cell doubling time was associated with
resistance to oxaliplatin (r¼0.64) and AMD473 (r¼0.60), but
not to the other two platinum drugs.
In order to identify genes and gene expression profiles
associated with cell doubling time and platinum drug sensitivity,
we measured the constitutive expression of approximately 4000
genes in the 14 human ovarian cancer cell lines using cDNA
microarray screening. RNA from each cell line was
33P-labelled and
hybridised to Research Genetics GF211 Named Human Genes
filters. Duplicate hybridisations were performed for each RNA
sample on different days using a different filter from the same
manufactured lot. Following background correction and global
means normalisation, variability was assessed for replicates by
determining a percent error associated with each gene element. Of
the 4132 elements examined, the majority of expression values
(66%) were associated with less than 35% error between
duplicates, 25% were associated with 25 to 50% error and 9%
were associated with greater than 50%. An important issue in
analysing microarray data is to determine which gene expression
values are most likely to be real or ‘validatable’. This problem was
approached by using quantitative RT–PCR measurements for 51
genes to guide the processing of the microarray data. We
considered a gene validatable if the Pearson or Spearman
correlation coefficient derived between the RT–PCR and micro-
array data was 0.6 or higher. Using the microarray data, a factor
was calculated based on the variability of the gene expression data
and the mean intensity of each gene across the panel of cell lines.
This was used to extract a data set that represented the genes that
had a higher probability of being validated by RT–PCR. Based on
this process, we estimated that approximately 70% of the genes in
the data set were ‘validatable’. The Web Supplement contains a full
list of the genes measured along with the correlation coefficients
calculated for the cell doubling times and platinum drug
sensitivities. The correlation between the RT–PCR and microarray
results are also provided.
Resistance to platinum drugs is multifactorial, thus it is unlikely
that the expression of a single gene would be strongly associated
with platinum drug sensitivity/resistance in a panel of unrelated cell
lines. We analysed our data set with the expectation that candidate
genes would emerge with lower correlation coefficients and higher
false discovery rates. Another obstacle to selecting causal
sensitivity/resistance genes is that some gene expression changes
may serve as markers of resistance, but not contributing
functionally to the phenotype. Despite these potential limitations,
we proceeded with the identification of genes associated with cell
proliferation and platinum drug sensitivity was carried out using
several methods including (1) correlation with respect to prolifera-
tion rate and drug sensitivity, (2) hierarchical clustering to identify
patterns of gene expression in the whole panel of cell lines and (3)
identifying differentially expressed genes in individual cell lines.
Spearman rank correlation coefficients were calculated for each
gene vs proliferation rate and platinum drug sensitivity in the 14
cell lines and the genes were ranked based on positive or negative
correlation. Using a correlation coefficient of 0.5 or greater as a
threshold, 47, 55 and 90 genes were associated with decreased
sensitivity to cisplatin, oxaliplatin and AMD473, respectively.
Table 4 lists genes that are most associated with resistance to
these three platinum drugs. The remainder of the list as well as the
entire data set is available in the Web Supplement. Of note,
increased Stat1 expression was associated with decreased cisplatin
Table 2 Doubling times and platinum drug sensitivities of human ovarian cancer cell lines
Platinum drug sensitivity (lM) (resistance relative to A2780)
Cell line Doubling time (h) Cisplatin Carboplatin Oxaliplatin AMD473
A2780 13.573.2 (1.0) 0.470.1 (1.0) 6.873.0 (1.0) 0.0370.01 (1.0) 1.170.2 (1.0)
A1847 26.670.6 (2.0) 4.471.1 (12.4) 88.3721.0 (13.1) 0.1870.04 (7.1) 11.873.2 (10.3)
SKOV3 32.473.6 (2.4) 6.772.1 (18.8) 96.874.6 (14.3) 4.7570.64 (186.3) 18.071.4 (15.7)
PEO1 25.476.4 (1.9) 1.071.2 (2.7) 13.673.9 (2.0) 0.3470.06 (13.3) 3.970.1 (3.4)
PEO4 24.175.2 (1.8) 9.170.2 (25.4) 120.5724.7 (17.9) 3.7570.85 (147.1) 18.970.8 (16.5)
OVCAR2 43.578.5 (3.2) 9.370.6 (25.9) 151.0743.8 (22.4) 5.3371.17 (208.8) 33.077.8 (28.8)
OVCAR3 22.170.5 (1.6) 4.671.1 (12.8) 48.376.7 (7.1) 5.3372.30 (208.8) 16.871.8 (14.6)
OVCAR4 39.171.9 (2.9) 1.670.0 (4.5) 19.071.4 (2.8) 0.2470.02 (9.2) 16.873.5 (14.7)
OVCAR5 17.571.1 (1.3) 2.470.6 (6.6) 35.074.2 (5.2) 0.2370.08 (9.0) 16.971.6 (14.8)
OVCAR7 44.6712.5 (3.3) 2.370.2 (6.4) 50.8722.4 (7.5) 9.8375.03 (385.6) 22.8711.2 (19.9)
OVCAR8 25.072.6 (1.9) 6.870.1 (19.1) 67.2728.5 (9.9) 0.2670.06 (10.0) 21.670.4 (18.8)
OVCAR10 15.371.7 (1.1) 17.971.6 (50.0) 173.3722.5 (25.7) 0.1170.03 (4.3) 13.471.2 (11.7)
UPN251 22.974.9 (1.7) 5.670.8 (15.7) 63.0712.7 (9.3) 3.1870.25 (124.5) 17.771.2 (15.4)
OAW42 18.271.4 (1.4) 0.970.3 (2.4) 13.372.9 (2.0) 0.0570.0 (1.8) 3.070.9 (2.6)
Table 3 Correlation coefficients
a derived from the relationships between the sensitivities of four platinum drugs in 14 human ovarian cancer cell lines
Platinum drug Cisplatin Carboplatin Oxaliplatin AMD473
Carboplatin r¼0.95, P¼0.000 — — —
Oxaliplatin r¼0.37, P¼0.198 r¼0.35, P¼0.215 — —
AMD473 r¼0.62, P¼0.019 r¼0.60, P¼0.025 r¼0.74, P¼0.003 —
Doubling time r¼0.12, P¼0.682 r¼0.27, P¼0.351 r¼0.64, P¼0.015 r¼0.60, P¼0.022
aSpearman’s rank test was used to calculate correlation coefficients and P-values.
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sand AMD473 sensitivity. Increased expression of chromatin
assembly factor-I and syndecan 4 was associated with decreased
sensitivity to both oxaliplatin and AMD473. Using a correlation
coefficient of  0.5 or less as a threshold, 38, 56 and 104 genes were
associated with decreased sensitivity to cisplatin, oxaliplatin and
AMD473, respectively. From these analyses, we selected a number
of candidates for validation by quantitative RT–PCR. Table 5 lists a
set of 23 such genes along with the Spearman rank correlation
coefficients derived with respect to platinum drug sensitivity. The
correlation between expression values obtained by cDNA micro-
array analysis and quantitative RT–PCR is also shown.
From the microarray data, it was evident that constitutive Stat1
expression was associated with both decreased cisplatin and
AMD473 sensitivity in the panel of cell lines (r¼0.65 and 0.76,
respectively). This was confirmed by quantitative RT–PCR
(Table 5). Stat1 protein levels were measured by Western blot
analysis of protein extracts prepared from the same set of cell lines
(Figure 1). The highest level of Stat1 expression was observed in
PEO4 and OVCAR2 cells. Quantitative analysis of the blot revealed a
high correlation between Stat1 protein levels and the expression
data obtained by RT–PCR (r¼0.94). The full-length cDNA for Stat1
was stably transfected into the multidrug-sensitive A2780 cell line.
Five zeocin-resistant colonies were propagated and assessed for
constitutive Stat1 expression by Western blot analysis (Figure 2).
Two of the five stable transfectants contained elevated Stat1 levels,
while the other three served as controls as no significant increase in
Stat1 expression was observed relative to the parental cells. This is
likely due to partial integration of the plasmid into the host genome
resulting in the expression of only the neomycin resistance gene.
The sensitivity of the clones to cisplatin, AMD473 and oxaliplatin
was measured using an MTT assay (Table 6). The two Stat1-
expressing clones exhibited decreased sensitivity to cisplatin and
AMD473, but not change in sensitivity to oxaliplatin. Following
several passages of the clones, Stat1 expression decreased and the
sensitivity of the cells to cisplatin and AMD473 was similar to that of
A2780 (data not shown). This could be due to the existence of a
small population of cells within the colony exhibiting decreased
Stat1 expression. Since Stat1 causes reduced cell proliferation, these
cells may be enriched in the overall cell population after multiple
passages. Pharmacologic inhibition of Jak/Stat signalling was
studied using the Jak2 inhibitor, AG490 (Figure 3). The optimal
concentration of AG490 required to inhibit Stat1 phosphorylation
was determined by Western blot analysis (data not shown).
OVCAR2 and PEO4 cells were pretreated with 50mM AG490
followed by treatment with a range of platinum concentrations.
AMD473 sensitivity was enhanced 4.1-fold in PEO4 cells (P¼0.001)
and 9.1-fold in OVCAR2 cells (P¼0.042) in the presence of AG490.
Although a 1.3- and 1.8-fold increase in cisplatin sensitivity was
observed in PEO4 and OVCAR2 cells, respectively, this effect was
not statistically significant. There was no significant change in the
sensitivity of either cell line to oxaliplatin following AG490
exposure.
DISCUSSION
In order to identify molecular determinants of chemotherapeutic
drug sensitivity and resistance, one must establish a clinically
Table 4 Genes associated with resistance to cisplatin, AMD473 and oxaliplatin as measured by cDNA microarray analysis
Unigene # Accession # Genes associated with cisplatin resistance r
a
Hs.20225 AA485750 Tuftelin interacting protein 11 0.749
Hs.444058 AA598621 Signal recognition particle receptor (‘docking protein’) 0.745
Hs.430541 AA431849 SON DNA binding protein 0.741
Hs.1706 AA291389 Transcriptional regulator ISGF3 gamma subunit 0.714
Hs.254321 T65118 Alpha-catenin 0.692
Hs.274485 AA464246 Major histocompatibility complex, class I, C 0.679
Hs.83469 AA496576 Transcription factor 11 (basic leucine zipper type) 0.670
Hs.458414 AA419251 Interferon-inducible protein 9–27 0.666
Hs.21486 AA488075 Signal transducer and activator of transcription 1 0.653
Hs.92004 R52541 EST 0.622
Unigene # Accession # Genes associated with AMD473 resistance r
Hs.470489 AA427561 Heparan sulphate proteoglycan (HSPG2) mRNA 0.881
Hs.8136 AA680300 Endothelial PAS domain protein 1 (EPAS1) 0.763
Hs.21486 AA488075 Signal transducer and activator of transcription 1 0.763
Hs.75238 AA426096 Chromatin assembly factor-I p60 subunit 0.754
Hs.504789 AA148737 Syndecan 4 (amphiglycan, ryudocan) 0.741
Hs.204238 AA400973 Neutrophil gelatinase-associated lipocalin precursor 0.736
Hs.433326 H79047 Insulin-like growth factor binding protein 2 0.736
Hs.435238 AA460827 Protein phosphatase I inhibitor 0.714
Hs.355214 H44051 Keratin, type I cytoskeletal 14 0.697
Hs.18799 R73545 Flotillin 2 0.697
Unigene # Accession # Genes associated with oxaliplatin resistance r
Hs.504789 AA148737 Syndecan 4 (amphiglycan, ryudocan) 0.859
Hs.437313 H11003 Endothelin 1 (alternative products) 0.742
Hs.80395 AA227885 Mal, T-cell differentiation protein 0.733
Hs.83577 AA195959 LIM protein MLP mRNA 0.728
Hs.194673 AA293653 Homolog of mouse MAT-1 oncogene mRNA 0.701
Hs.410104 H43049 Serine/threonine-protein kinase receptor R3 precursor 0.701
Hs.470843 AA039370 Transcriptional enhancer factor TEF-1 0.692
Hs.75238 AA426096 Chromatin assembly factor-I p60 subunit mRNA 0.688
Hs.75216 AA598513 Protein tyrosine phosphatase, receptor type, f polypeptide 0.679
Hs.251754 AA683520 Antileukoproteinase 1 precursor 0.674
The top 10 genes associated with decreased sensitivity to each drug is listed. The full set of genes is available in the Web Supplement.
aThe Spearman’s rank correlation
coefficient calculated for each gene and each platinum drug is listed.
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srelevant model. Several groups have produced drug-resistant
cancer cell lines; however, most of these have been derived
artificially by exposing sensitive cells repeatedly to increasing
concentrations of a chemotherapeutic drug. Although such models
have their own merits, we have approached the problem of
resistance by studying a panel of unrelated tumour cell lines. These
cell lines not only exhibit a wide range of platinum drug sensitivity
but were also established from the tumours of ovarian cancer
patients who were either untreated or treated with platinum-based
chemotherapy. In a previous study (Johnson et al, 1997), we
defined the cellular pharmacology of cisplatin in these cell lines
and discovered that platinum–DNA damage tolerance is a major
mechanism of cisplatin resistance. To determine the molecular
basis for this potentially clinically relevant resistance mechanism,
we applied cDNA microarray analysis to the same set of cell lines
in the present study. One limitation to our model is the overall
number of cell lines examined relative to the large amount of
expression data obtained. This significantly increases the number
of genes that are found to be associated with the sensitivity/
resistance phenotype. Another potential limitation is the selection
of the MTT assay to measure platinum sensitivity. This assay is
Table 5 Results of real-time quantitative RT–PCR analysis of gene expression associated with resistance to platinum drugs
a. Data for the remainder of the
genes analysed are available in the Web Supplement
Gene Cisplatin Oxaliplatin AMD473 Microarray/PCR correlation
Signal transducer and activator of transcription 1 0.69 0.53 0.87 0.89
Transcriptional regulator ISGF3 gamma subunit 0.60 0.55 0.54 0.74
Interferon-induced 17kDa protein 0.52 0.15 0.56 0.66
Interferon-inducible protein (p78) 0.42 0.57 0.73 0.57
Epiregulin 0.41 0.51 0.83 0.41
Integrin beta-1 0.41 0.31 0.46 0.48
Lipocalin 2 0.40 0.62 0.75 0.87
Cadherin 6 0.35 0.89 0.63 0.25
Nicotinamide N-methyltransferase (NNMT) 0.34 0.35 0.63 0.89
TNF receptor superfamily, member 11b 0.33 0.42 0.67 0.75
Protein kinase C, iota 0.32 0.54 0.63 0.78
Interferon-induced protein 1–8D 0.28  0.12  0.03 0.85
Antileukoprotease 0.23 0.81 0.61 0.90
S100 calcium binding protein A2 0.22 0.47 0.36 0.88
Endothelin 1 0.21 0.45 0.42 0.76
Interleukin 1 0.17 0.44 0.66 0.12
Endothelial domain protein 1 (EPAS1) 0.16 0.29 0.61 0.58
Thymosin 0.15 0.54 0.56 0.93
Ceramide glucosyltransferase 0.15 0.31 0.34 0.83
Matrix metalloproteinase 7 0.02 0.39 0.46 0.80
Interleukin 8  0.03 0.47 0.47 0.86
Interleukin 6  0.07 0.18 0.29 0.72
S100 calcium binding protein A10  0.09 0.63 0.15 0.84
aSpearman’s rank test was used to calculate correlation coefficients.
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Figure 1 Expression of Stat1 protein in a panel of 14 human ovarian
cancer cell lines. (A) Equal amounts (25mg) of whole-cell extract were
resolved by SDS–PAGE and analysed by Western blot analysis using anti-
Stat1 antibody; (B) comparison of the data obtained by Western blot
analysis and quantitative ‘real-time’ RT–PCR. Measurements were made
from each cDNA reaction in duplicate and normalised based on the
average of the normalized expression of four housekeeping genes.
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Figure 2 Isolation of Stat1-expressing clones. The full-length Stat1
cDNA was transfected into A2780 cells. Zeocin-resistant clones were
isolated, propagated and assessed for Stat1 expression by Western blot
analysis. As a positive control, A2780 cells were transiently transfected with
the same Stat1 cDNA construct.
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seasy to conduct and provides data rapidly; however, the data may
be subject to some variability when compared to that obtained by
other cytotoxicity assays. In support of our approach, however,
Perez et al (1993) demonstrated previously that cisplatin
sensitivity as measured by the MTT assay correlates well with
that of the sulphorhodamine B and clonogenic assays.
The variability observed in cytotoxicity profiles between
platinum drugs is due, in part, to the composition of their carrier
ligands. This ultimately affects the structure and conformation of
the resulting platinum–DNA adducts. Although cisplatin and
carboplatin contain different leaving groups, the structure of their
reactive species is the same. Thus, both drugs show very similar
cytotoxicity profiles. Oxaliplatin exhibited a unique cytotoxicity
profile compared to that of cisplatin and carboplatin, which is
consistent to that observed by others (Burchenal et al, 1980; Rixe
et al, 1996). We also examined the sensitivity of the cell lines to
AMD473, a platinum complex that has been shown previously to
circumvent the acquired cisplatin resistance phenotypes in some
in vitro models (Raynaud et al, 1997). Crossresistance of the cells
to AMD473 was observed for some of the cell lines, however, the
correlation coefficients obtained between AMD473 and the other
three platinum drugs indicate that the structure of this complex
imparts somewhat unique activity. We have shown previously that
many of the cisplatin-resistant cell lines in our panel exhibit
significant crossresistance to nonplatinum chemotherapeutic
agents (Johnson et al, 1997). This suggests that tolerance or
antiapoptotic mechanisms may be responsible for resistance in
these cells resulting in decreased sensitivity to structurally
unrelated drugs.
One can approach the problem of identifying resistance genes
using several strategies. First, correlation coefficients can be used
to find genes that are positively and negatively associated with
chemoresistance across the entire panel of cell lines. Secondly, one
can use supervised or unsupervised methods such as hierarchical
clustering to identify gene expression patterns associated with a
subset of resistant cells. Finally, one can identify genes that are
significantly up- or downregulated in individual cells relative to all
of the cell lines. The most effective strategy may be to use a variety
of statistical approaches for gene discovery. Validating gene
expression is also critical to the identification of candidate genes
for functional studies. For expression profiling studies, quantita-
tive ‘real-time’ RT–PCR offers a rapid and sensitive method for
this step. Another important use of quantitative RT–PCR data is to
facilitate the processing of microarray data to include only the set
of genes that are considered ‘validatable’. Genes that are highly
Table 6 Sensitivity of individual STAT1 clones to various chemother-
apeutic drugs
Stat1
clone
Stat1
expression
Cisplatin IC50
(lM)
a
AMD473 IC50
(lM)
Oxaliplatin
IC50 (lM)
Parental   0.2370.05 (1.0) 2.470.5 (1.0) 0.03870.007 (1.0)
1 + 0.7470.71 (3.2) 9.379.8 (4.0) 0.04470.009 (1.2)
2 +++ 0.9570.18 (4.1)* 11.875.7 (5.0)* 0.06570.016 (1.7)
3   0.2470.07 (1.1) 3.271.6 (1.3) 0.03470.003 (0.9)
4   0.2370.04 (1.0) 5.475.7 (2.3) 0.04370.011 (1.1)
5   0.3670.05 (1.5) 3.271.0 (1.3) 0.02670.003 (0.8)
aThe standard deviation is provided and the relative resistance to parental A2780
cells is shown in parentheses. *Clones that are statistically different based on a t-test
with Pp0.05.
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Figure 3 Effect of AG490 on platinum drug sensitivity in OVCAR2 and PEO4 cells. Cells were pretreated with 50mM AG490 for 1h followed by
exposure to a range of platinum drug concentrations. Survival was determined after 72h using the MTT reagent. The results are the average of triplicate
measurements obtained on at least two separate occasions. The error bars represent the standard deviation of each data point.
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sexpressed and that exhibit high variability in expression have a
high probability of correlating positively with RT–PCR data. In
contrast, microarray data that represents low variability and low
levels of gene expression will correlate poorly with RT–PCR data.
In this study, we used RT–PCR data to guide the processing of our
microarray data in order to obtain a set of ‘validatable’ genes. This
is likely to be the first report that describes such an approach for
cleaning a set of semiquantitative array data.
We focused our functional studies on the Jak/Stat signalling
pathway for several reasons. A positive correlation was observed
between Stat1 expression and decreased sensitivity to both
cisplatin and AMD473. The relatively high correlation coefficients
obtained were due, in part, to a higher expression of Stat1 in both
the OVCAR2 and PEO4 cell lines. In addition, the PEO4 cell line
contained significantly higher levels of Stat1 mRNA (15-fold) and
protein (six-fold) as compared to its drug-sensitive counterpart,
PEO1. We also observed a positive correlation between the
expression of interferon-stimulated gene factor 3 (ISGF3)g (IRF9,
p48), a transcription factor subunit that forms a heterodimer with
Stat1, and decreased sensitivity to cisplatin (r¼0.70) and AMD473
(r¼0.40). Interestingly, the PEO4 cell line also contained elevated
expression levels of other interferon-inducible genes when
compared to the other cell lines. These included interferon
alpha-induced 11.5kDa protein, interferon-inducible protein 9–
27, interferon-inducible protein p78, interferon-induced 17kDa
protein, interferon-inducible protein 1–8D, interferon-induced
56kDa protein and interferon-inducible protein 1–8U. The
upregulation of these genes may be due, in part, to elevated levels
of the ISGF3 transcription factor complex. In fact, we evaluated the
constitutive activity of this complex using an ISRE element linked
to a luciferase reporter gene and found that PEO4 cells exhibit a
two-fold higher level of ISRE transcriptional activity as compared
to platinum-sensitive PEO1 cells (data not shown).
The Jak/Stat pathway represents a major signalling pathway that
enables a cell to interpret and react to inflammatory signals and
cytokines (Leonard and O’Shea, 1998). This pathway utilises
cytosolic transcription factors known as Stat’s (signal transducer
and activator of transcription) to transduce an extracellular signal
to the nucleus. ISGF3 is a multisubunit transcription factor
required for transcriptional activation of interferon-stimulated
genes in response to interferons and other cytokines. The ISGF3
complex contains two major components: ISGF3g and ISGF3a, the
latter comprised of two Stat proteins (Stat1a, Stat1b or Stat2).
Treatment of cells with interferons or cytokines leads to receptor-
mediated signal transduction and tyrosine phosphorylation of the
Stat subunits by Janus kinases (Jak1, Jak2, Jak3 or Tyk2). The
phosphorylated complex is subsequently translocated to the
nucleus for target gene activation. A role for these transcription
factors in resistance to platinum drugs has not been reported
previously; however, a report by Luker et al (2001) showed that
overexpression of ISGF3 (IRF9) confers resistance to paclitaxel. In
their study, paclitaxel resistance was not observed following
transfection of Stat1 or Stat2 cDNAs. Our functional studies
demonstrated that Stat1 overexpression confers resistance to
cisplatin and AMD473, but not to oxaliplatin. Conversely,
inhibition of Jak/Stat signaling using the Jak2 inhibitor, AG490,
resulted in increased sensitivity to cisplatin and AMD473, but not
to oxaliplatin. Our previous study indicated that PEO4 and
OVCAR2 cells have a relatively high level of platinum–DNA
damage tolerance as compared to the other cell lines in this panel
(Johnson et al, 1997); thus, we suspect that Jak/Stat signalling may
be involved in preventing cell death following DNA damage. This
may occur indirectly through the induction of antiapoptotic genes
or by reducing cell proliferation, thus enabling more time to repair
DNA lesions. We observed that some cell lines exhibiting increased
platinum drug resistance do not contain elevated levels of Stat1.
For example, OVCAR10 is 50- and 12-fold resistant to cisplatin and
AMD473, respectively, relative to A2780 cells and shows a high
level of platinum–DNA damage tolerance (Johnson et al, 1997).
This is not unexpected since our study included a panel of
unrelated cell lines, and given the fact that platinum resistance is
multifactorial, a number of other potential mechanisms could be
responsible.
Other investigators have reported an effect of AG490 on the
survival of various types of cancer including breast (Burke et al,
2001; Garcia et al, 2001), leukaemia (Spiekermann et al, 2001),
myeloma (De Vos et al, 2000), ovarian (Burke et al, 2001; Arbel
et al, 2003), pancreatic (Toyonaga et al, 2003) and prostate (Ni
et al, 2000). Since Jak2 is capable of phosphorylating a number of
downstream targets such as Stat1, Stat3 and Stat5, the effect of
AG490 on platinum sensitivity in our model may be the result of
inhibiting multiple survival signalling pathways. Interestingly, we
did not observe increased sensitivity to nonplatinum chemother-
apeutic drugs when combined with AG490 (data not shown). We
also found that cells that do not express relatively high levels of
Stat1 such as A2780 or PEO1 cells are not sensitised to cisplatin or
AMD473 in the presence of AG490. This suggests that, although
such inhibitors may be cytotoxic as single agents, increased
therapeutic benefit may not be observed when combined with
platinum drugs in tumours that do not exhibit increased Jak/Stat
signalling. Thus, identifying the subset of patients whose tumours
exhibit upregulation of this pathway could be useful for combined
therapy with a platinum drug. This observation emphasises the
importance of tailoring treatment to the expression profile of a
particular tumour. In addition to Stat1, we selected a number of
other genes for validation experiments based, in part, on their
association with platinum drug sensitivity (Table 5). Among these
are included extracellular matrix proteins, cytokines, growth
factors, interferon-inducible genes and calcium binding proteins.
Currently, there are no specific studies to suggest these genes are
involved in cisplatin resistance; however, one may speculate a role
for them in prosurvival signalling based on their putative
functions.
Similar to the resistance phenotype, sensitivity to platinum
drugs may be conferred by increased expression of a variety of
genes. Our analysis of oxaliplatin and AMD473 sensitivity revealed
a common theme, which was the expression of a considerable
number of transcripts involved in RNA transport and processing.
These included the heterogeneous ribonucleoproteins A/B, H, A1,
A2/B1, R, C, hPrp4 and several pre-mRNA splicing factors. A role
for these genes in conferring platinum sensitivity is unknown;
however, one theory is that they may create alternatively spliced
forms of some mRNA species, thus altering their function. There
are reports of this phenomenon in the literature. Alternatively
spliced genes have been discovered that confer opposing apoptotic
effects including variants of survivin, Fas receptor and CC3, a
metastasis suppressor (Conway et al, 2000; Jenkins et al, 2000;
Whitman et al, 2000). It is unlikely that cDNA microarray analysis
can identify splice variants since the technique relies on
hybridisation. However, the observed differential expression of
genes involved in RNA processing suggests that analysing ovarian
cancer cells for alternatively spliced transcripts may reveal novel
mechanisms of platinum drug sensitivity.
In recent years, a number of reports have provided gene
expression profiles associated with intrinsic and acquired drug
resistance (Scherf et al, 2000; Dan et al, 2002; Higuchi et al, 2003).
These studies were carried out using various microarray platforms
and model systems. Nonetheless, we compared our data to that
produced from other studies to find platinum sensitivity and
resistance genes. The gene expression database established by
Scherf et al (2000) utilised growth inhibition data for the NCI60
cell lines along with expression measurements for 1376 genes. This
panel of cell lines contained only six ovarian cancer cell lines, so
instead of comparing our data to this small subset of cells, we
compared data for the entire panel. We did not observe
commonality in the two data sets for genes associated with
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scisplatin sensitivity; however, the expression of three genes
(ISGF3g, MSSP-1 and transforming growth factor (TGF)-beta.)
was found to be associated with cisplatin resistance. In the present
study, we provide correlative evidence for ISGF3g expression and
decreased cisplatin sensitivity. There are no reports implicating
MSSP-1 (RBMS1, RNA binding motif, single-stranded interacting
protein) in cisplatin resistance. MSSP-1 possesses versatile
functions including stimulation of DNA replication, transcrip-
tional regulation, apoptosis induction and cell transformation
coordinated by c-Myc (Niki et al, 2000). TGF-beta is a multi-
functional peptide that controls proliferation, differentiation
and other functions in many cell types. Teicher et al (1997)
examined the role of TGF-beta in multidrug resistance by
transfecting TGF-beta into murine mammary carcinoma cells. In
monolayer culture, the TGF-beta-expressing cells were not
resistant to cisplatin relative to control cells, but were markedly
resistant when grown as solid tumours in mice. We did not find
similarities in our set of putative cisplatin resistance genes when
compared to the data provided in two other studies. Dan et al
(2002) examined the expression of 9216 genes in 39 human cancer
cell lines in relation to growth inhibition data for 55 anticancer
drugs. The aldo-keto reductase gene and damage-specific DNA
binding protein 2 were associated with sensitivity to at least 20 of
the drugs including cisplatin and expression of the LIM domain
kinase 2 gene was associated with resistance. Higuchi et al (2003)
approached the problem of identifying cisplatin resistance genes
using acquired cisplatin resistance head and neck cancer cells. This
group reported alterations in the expression of a glycoprotein
hormone and membrane proteins in this model. These results
underscore not only the potential complexity of platinum drug
sensitivity and resistance but also demonstrates the heterogeneity
in results that are obtained from different cell models and
microarray platforms.
In summary, high-throughput technologies such as cDNA
microarray analysis have facilitated the discovery of the molecular
determinants of chemotherapeutic drug sensitivity/resistance.
However, expression profiling is a relatively new tool, thus its
potential value for drug target discovery is unclear at this early
stage. This will become increasingly apparent as the number of
pharmacogenomic databases increase and comparisons can be
made across different platforms and cellular models. Our study
provides a significant amount of gene expression data that may be
useful for other investigators interested in chemotherapeutic drug
resistance. The results of our study also emphasise the importance
of validating results obtained by cDNA microarray analyses. From
these data, we have shown that not only is increased Stat1
expression associated with resistance to some platinum drugs but
also the Jak/Stat signalling pathway may be a useful target for the
design of inhibitors. Although not in the scope of the present
study, functional studies of other genes in this data set may lead to
the identification of potential targets for enhancing platinum drug
sensitivity.
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